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Abstract
We examined the association between HNF1B variants identified in a recent genome-wide association study and
endometrial cancer in two large case-control studies nested in prospective cohorts: the Multiethnic Cohort Study (MEC) and
the Women’s Health Initiative (WHI) as part of the Population Architecture using Genomics and Epidemiology (PAGE) study.
A total of 1,357 incident cases of invasive endometrial cancer and 7,609 controls were included in the analysis (MEC: 426
cases/3,854 controls; WHI: 931cases/3,755 controls). The majority of women in the WHI were European American, while the
MEC included sizable numbers of African Americans, Japanese and Latinos. We estimated the odds ratios (ORs) per allele
and 95% confidence intervals (CIs) of each SNP using unconditional logistic regression adjusting for age, body mass index,
and four principal components of ancestry informative markers. The combined ORs were estimated using fixed effect
models. Rs4430796 and rs7501939 were associated with endometrial cancer risk in MEC and WHI with no heterogeneity
observed across racial/ethnic groups (P$0.21) or between studies (P$0.70). The ORper allele was 0.82 (95% CI: 0.75, 0.89;
P=5.63610
26) for rs4430796 (G allele) and 0.79 (95% CI: 0.73, 0.87; P=3.77610
27) for rs7501939 (A allele). The associations
with the risk of Type I and Type II tumors were similar (P$0.19). Adjustment for additional endometrial cancer risk factors
such as parity, oral contraceptive use, menopausal hormone use, and smoking status had little effect on the results. In
conclusion, HNF1B SNPs are associated with risk of endometrial cancer and that the associated relative risks are similar for
Type I and Type II tumors.
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Introduction
Endometrial cancer is the most common gynecological cancer
in developed countries. A recent genome-wide association study
(GWAS) identified common single nucleotide polymorphisms
(SNPs) in HNF1B associated with endometrial cancer risk in
women of European background [1]. The same SNPs,
rs4430796 and rs7501939, are also associated with prostate
cancer [2] and type 2 diabetes [3,4]. We examined the
association between these SNPs and risk of endometrial cancer
in two large prospective cohort studies with comprehensive risk
factor data: the Multiethnic Cohort Study (MEC) and the
Women’s Health Initiative (WHI), as part of the Population
Architecture using Genomics and Epidemiology (PAGE) study
[5]. We also examined the associations between HNF1B and
endometrial cancer across racial/ethnic groups and tumor
histological types, and effect modification by known endometrial
cancer risk factors.
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PAGE is an ancillary study to both WHI and MEC, and has
been approved by the WHI and MEC steering committees. The
PIs for the PAGE studies within WHI and MEC have further
authority for analyses within the scope of the original applications.
Study population
PAGE study is a National Human Genome Research Institute
(NHGRI)-supported collaboration with a primary focus of deep
characterization of well-replicated genetic risk variants identified in
GWASand their relationshipsto variousphenotypes and traits (e.g.,
lipids, diabetes, heart disease, cancers) in diverse epidemiologic
studies. Included in the characterization process is 1) replication of
the original association in a population of similar genetic ancestry as
the original GWAS, 2) generalization of the association to diverse
populations such as African Americans, Asians, Hispanic/Mexican
Americans, and other groups, 3) identification of gene-environment
interactions, and 4) identification of pleiotropy. The details of
PAGE design and methods have been presented by Matise et al [5].
The PAGE study samples were drawn from four large population-
based studies or consortia [5]; however, the current analysis only
included women from the MEC and the WHI. The MEC is a
prospective cohort study consisting of 215,251 adult men and
women living in Hawaii and California predominantly from five
populations: European American, African American, Native
Hawaiian, Japanese, and Latino (Hispanic/Mexican Americans)
[6]. A subset of cohort participants (,70,000) has available DNA
samples. Incident cases of endometrial cancer were identified
throughcohort linkage to the population-based cancerSurveillance,
Epidemiology, and End Results (SEER) registries in California and
Hawaii. Controls were selected from female cohort participants
without a self-reported hysterectomy at baseline and who were free
of cancer as at December 31, 2008. Controls were individually
matched to cases based on age at cohort entry, race/ethnicity, and
study area (Hawaii or California). The MEC endometrial cancer
case-control study included 426 invasive endometrial cancer cases
and 3,854 controls. The WHI is comprised of an observational
study and four clinical trials covering the components of dietary
modification, hormone therapy, separately for women with and
without a uterus, and supplementation of calcium/vitamin D [7].
The study consists of 161,808 postmenopausal women from various
racial/ethnic groups. Incident cases of endometrial cancer in the
cohort were identified through self-report, which was ascertained at
least annually and confirmed by clinicians after reviewing the
pathology reports [8]. Controls were selected from cohort
participants without a self-reported hysterectomy at baseline and
who were free of cancer through September 1, 2009. Controls were
individually matched to cases based on age at baseline, date of
enrollment, race/ethnicity, and trial arms. The WHI endometrial
cancer case-control study included 931 invasive endometrial cancer
cases and 3,755 controls.
Tumor histology
We used the International Classification of Diseases for
Oncology (ICD-O-3) code to classify endometrial cancer cases as
Type I or Type II [9–11]. Unopposed estrogens are suspected to
affect Type I but not Type II tumors [12]. Type I included
endometrioid (ICD-O-3 code: 8380, 8381, 8382, 8383), adeno-
carcinoma tubular (8210, 8211), papillary adenocarcinoma (8260,
8262, 8263), adenocarcinoma with squamous metaplasia (8570),
mucinous adenocarcinoma (8480, 8481), and adenocarcinoma
NOS (8140). Type II included clear cell (8310), serous (8441),
papillary serous (8460, 8461), squamous cell (8050, 8070, 8071,
8072), adenosquamous (8560), small cell carcinoma (8041), and
mixed cell adenocarcinoma (8323). Cases with a sarcoma diagnosis
were not included in the analysis.
SNP selection and genotyping
The two HNF1B SNPs (rs4430796 and rs7501939) were part of
167 (MEC) and 183 (WHI) well-replicated genetic risk variants
identified from GWAS genotyped in the PAGE study to explore
pleiotropic effects on several cancer sites. Genotyping was
performed using the TaqMan Open Array Genotyping System
(Life Technologies/Applied Biosystems) as part of the PAGE
initiative. The average genotype completion rate was 98.0% in the
MEC and 99.9% in the WHI. The concordance of blinded
duplicates was 99.7% in the MEC and 99.5% in the WHI. Hardy-
Weinberg Equilibrium (HWE) for each allele was assessed in each
racial/ethnic group in controls; no deviation from HWE was
observed (at the P,0.01 level) across more than one racial/ethnic
group, suggesting that such deviations are likely due to chance and
not to genotyping error.
Statistical analysis
Known risk factors for endometrial cancer (i.e. parity, oral
contraceptive use, menopausal hormone use, smoking status, and
diabetes status were obtained from the baseline questionnaire data.
Per allele odds ratios (ORs) and 95% confidence intervals (CIs) for
the SNP-endometrial cancer association were calculated using
unconditional logistic regression. Models were adjusted for age
(continuous), body mass index (BMI) (,25, 25-,30, $30 kg/m
2),
and the top four ancestry principal components. Principal
components derived from .100 ancestry informative markers
were estimated using the EIGENSTRAT method [13]. Parity,
oral contraceptive use, menopausal hormone use, smoking status,
and diabetes status were considered as potential confounders. Test
of interaction with race/ethnicity and potential effect modification
by endometrial cancer risk factors was assessed using log-likelihood
test statistics comparing models with and without the interaction
term (cross product between the SNP and race/ethnicity or risk
factor of interest). The combined ORs and 95% CIs were
estimated from each study’s OR using a fixed effects model and
between-study heterogeneity was examined using the Q test
statistics. We used polytomous logistic regression to calculate ORs
and 95% CIs for Type I and Type II endometrial cancer. All
racial/ethnic groups were included in this subgroup analysis. All P
values are two-sided.
Results
The characteristics of cases and controls in the MEC and the
WHI are shown in Table 1. The mean ages of cases and controls
were similar in each study. The majority of women in the WHI
were European American (93.2% of cases and 80.3% of controls);
there were very few Asian/Pacific Islander (n=8) and Latino
(n=20) cases. The MEC included sizable proportions of women
from other racial/ethnic groups: 20.5% African American, 30.3%
Japanese, and 18.7% Latino. Compared to controls, cases were
heavier, more likely to have fewer births, and to be diabetic. Cases
were less likely to have used OCs or to have ever smoked.
We found that rs4430796 and rs7501939 were associated with
risk of endometrial cancer in European Americans in the MEC
and the WHI (Table 2). The combined ORper allele was 0.83 (95%
CI: 0.75, 0.92; P=4.00610
24) for rs4430796 (G allele) and 0.79
(95% CI: 0.71, 0.88; P=1.30610
25) for rs7501939 (A allele). No
heterogeneity between studies was observed (P$0.59). The
rs4430796 and rs7501939 were in strong linkage disequilibrium
HNF1B and Endometrial Cancer Risk
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2=0.61 in the MEC;
r
2=0.66 in the WHI).
In the MEC, consistent associations were observed in African
Americans, Hawaiians, Japanese and Latinos, i.e. reduced risk
associated with the G allele of rs4430796 or with the A allele of
rs7501939 (Table 2). There were limited numbers of non-
European descent women in the WHI, especially the Asian/
Pacific Islander group (8 cases and 161 controls). In African
Americans and Latinos, we observed consistent associations with
those observed among European Americans. No evidence was
observed of heterogeneity in the ORs by race/ethnicity (P$0.21).
Combining the MEC and the WHI results, the ORper allele ranged
between 0.74 and 0.80 for rs4430796 and between 0.73 and 0.80
for rs7501939 in African Americans, Asians/Pacific Islanders, and
Latinos. The two SNPs were in high LD in Asians (r
2=0.80) and
Latinos (r
2=0.65) and in lower LD in African Americans
(r
2=0.33).
In the analysis of all race/ethnicity groups combined, the
ORper allele for rs4430796 was 0.80 (95% CI: 0.69, 0.93;
P=0.0048) and 0.83 (95% CI: 0.75, 0.92; P=0.00059) in the
MEC and the WHI, respectively (Table 2). The all groups’
ORper allele for rs7501939 was 0.80 (95% CI: 0.68, 0.94;
P=0.0068) and 0.79 (95% CI: 0.71, 0.88; P=1.87610
25)i n
the MEC and the WHI, respectively. When we combined the
results from the MEC and the WHI, the ORper allele was 0.82
(95% CI: 0.75, 0.89; P=5.63610
26) for rs4430796 and 0.79
(95% CI: 0.73, 0.87; P=3.77610
27) for rs7501939. No
heterogeneity between studies was observed (P$0.70). Further
adjustment for parity, oral contraceptive use, menopausal
hormone use, smoking status, diabetes status and clinical trial
participation (dietary modification, hormone therapy, or obser-
vational study) for the WHI had little effect on the results.
The associations of HNF1B SNPs with Type I and Type II
tumors are shown in Table 3. In both studies, rs4430796 and
rs7501939 were significantly associated with Type I tumors. Both
SNPs were also associated with reduced risk of Type II tumors, but
the association was only significant for rs4430796 in the MEC. No
evidence of heterogeneity between studies was observed (P$0.18).
The combined ORper allele for rs4430796 was 0.83 (95% CI: 0.76,
0.90; P=2.79610
25) for Type I tumors and 0.78 (95% CI: 0.61,
0.99; P=0.041) for Type II tumors. The combined ORper allele for
rs7501939 was 0.80 (95% CI: 0.73, 0.87; P=1.00610
26) for Type
I tumors and 0.75 (95% CI: 0.58, 0.95; P=0.020) for Type II
tumors. Neither study found significant differences between the
associations of HNF1B SNPs with Type I and Type II tumors
(P$0.19 in the MEC; P$0.80 in the WHI).
To determine whether the associations of HNF1B variants and
endometrial cancer were influenced by diabetes, we examined the
OR for the SNP-endometrial cancer relationship among diabetics
and non-diabetics separately (Table 4). Significant associations
were observed only among non-diabetics in both studies. In the
WHI, the test for interaction was statistically significant for
rs4430796 (P=0.028) and borderline significant for rs7501939
(P=0.054). No significant interaction was observed in the MEC.
We also examined effect modification of the association between
HNF1B SNPs and endometrial cancer by BMI, parity, OC use,
menopausal hormone use and smoking status (Table S1 and S2)
and found no significant interaction.
Discussion
We show that the HNF1B SNPs (rs4430796 and rs7501939)
identified in a recent endometrial cancer GWAS [1] are associated
with endometrial cancer risk in two independent studies and that
the associations were observed across multiple racial/ethnic
groups. We also show that similar associations are seen for both
Type I and Type II tumors and across all categories of BMI,
parity, OC use, menopausal hormone use and smoking status.
Table 1. Characteristics of Cases and Controls in the
Multiethnic Cohort Study (MEC) and the Women’s Health
Initiative Study (WHI).
MEC WHI
Cases
N=426
Controls
N=3854
Cases
N=931
Controls
N=3755
Mean age
1 (SD) 65.6 (8.3) 66.2 (8.8) 63.7 (7.0) 64.6 (7.4)
Race/ethnicity, n (%)
European American 106 (24.9) 813 (21.1) 868 (93.2) 3037 (80.3)
African American 68 (16.0) 820 (21.3) 35 (3.8) 350 (9.2)
Hawaiian 27 (6.3) 344 (8.9)
Asian
2/Pacific Islander 121 (28.4) 1204 (31.2) 8 (0.9) 161 (4.3)
Latino 104 (24.4) 673 (17.5) 20 (2.1) 207 (5.5)
Body mass index
(kg/m
2), n (%)
,25 146 (34.3) 1792 (46.5) 306 (32.9) 1411 (37.6)
25-,30 113 (26.5) 1220 (31.7) 253 (27.2) 1293 (34.4)
$ 30 163 (38.3) 796 (20.7) 364 (39.1) 1018 (27.1)
Missing 4 (0.9) 46 (1.2) 8 (0.9) 33 (0.9)
Parity, n (%)
Nulliparous 73 (17.1) 454 (11.8) 149 (16.0) 509 (13.6)
1–2 150 (35.2) 1313 (34.1) 322 (34.6) 1213 (32.3)
3–4 144 (33.8) 1405 (36.5) 360 (38.7) 1390 (37.0)
$5 56 (13.1) 648 (16.8) 97 (10.4) 632 (16.8)
Missing 3 (0.7) 34 (0.9) 3 (0.3) 11 (0.3)
Oral contraceptive use, n
(%)
Never 238 (55.9) 2006 (52.1) 576 (61.9) 2368 (63.1)
Ever 178 (41.8) 1766 (45.8) 355 (38.1) 1387 (36.9)
Missing 10 (2.4) 82 (2.1)
Menopausal hormone use,
n( % )
Never 252 (59.2) 1877 (48.7) 361 (38.8) 2196 (58.5)
Past 65 (15.3) 578 (15.0) 124 (13.3) 539 (14.4)
Current 94 (22.0) 1258 (32.6) 444 (47.7) 1018 (27.1)
Missing 15 (3.5) 141 (3.7) 2 (0.2) 2 (0.1)
Smoking status, n (%)
Never 263 (61.7) 2209 (57.3) 486 (52.2) 1956 (52.1)
Past 131 (30.8) 1139 (29.6) 395 (42.4) 1490 (39.7)
Current 27 (6.3) 458 (11.9) 40 (4.3) 264 (7.0)
Missing 5 (1.2) 48 (1.3) 10 (1.1) 45 (1.2)
Diabetes, n (%)
No 388 (91.1) 3556 (92.3) 887 (95.3) 3610 (96.1)
Yes 38 (8.9) 298 (7.7) 44 (4.7) 143 (3.8)
Missing 2 (0.1)
1Age at diagnosis for cases and age at blood draw for controls in the MEC; age
at baseline for cases and controls in the WHI.
2Japanese in the MEC, approximately 25% Chinese, 50% Japanese, and 25%
other groups in the WHI.
doi:10.1371/journal.pone.0030390.t001
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study (ORrs4430796=0.83; ORrs7501939=0.79) were similar to
those reported by the initial GWAS (ORrs4430796=0.84;
ORrs7501939=0.85) [1]; the most significant SNP in the GWAS
(rs4430796) however was not the most strongly associated SNP in
this study, which underlies the fact that neither SNP is the causal
SNP.
HNF1B (formerly known as TCF2) is a transcription factor that
encodes three isoforms: isoforms A and B which act as
transcriptional activators and isoform C which acts as a
transcriptional repressor [14]. Rare mutations in HNF1B have
been associated with maturity-onset diabetes of the young subtype
5 (MODY5), renal cysts, pancreatic atrophy, and uterine
abnormalities caused by incomplete Mullerian duct fusion and
Mullerian duct aplasia [15,16]. Differential expression of HNF1B
has been associated with prostate cancer recurrence [17] and
differential expression of HNF1B isoforms has been found in
normal prostate and prostate cancer tissues [18]. The functional
significance of the two HNF1B SNPs examined here is unknown,
although a lymphocyte-derived gene expression analysis showed a
significant association between rs4430796 and HNF1B expression
in individuals of European ancestry but not in individuals of
African ancestry [1].
The G allele of rs4430796 which is associated with decreased
risk of endometrial cancer, has been associated with a decreased
risk of prostate cancer but not with other cancers such as breast,
Table 2. Association between HNF1B variants and endometrial cancer.
rs4430796 (A/G) rs7501939 (G/A)
Race/ethnicity Study
Number of
cases/
controls
Allele Frequency
Cases/Controls OR
1 (95% CI) P-value
Allele Frequency
Cases/Controls OR
1 (95% CI) P-value
European American MEC 106/813 0.45/0.51 0.79 (0.59, 1.05) 0.11 0.34/0.41 0.73 (0.53, 0.99) 0.045
WHI 868/3037 0.45/0.49 0.84 (0.75, 0.93) 0.0015 0.36/0.41 0.80 (0.72, 0.90) 0.00015
Combined
3 0.83 (0.75, 0.92) 4.00610
24 0.79 (0.71, 0.88) 1.30610
25
African American MEC 68/820 0.61/0.64 0.80 (0.55, 1.16) 0.23 0.48/0.51 0.88 (0.61, 1.26) 0.47
WHI 35/350 0.59/0.65 0.81 (0.49, 1.35) 0.41 0.41/0.52 0.61 (0.35, 1.02) 0.065
Combined
3 0.80 (0.59, 1.09) 0.15 0.78 (0.58, 1.06) 0.11
Asian/Pacific Islander MEC 121/1204 0.31/0.38 0.74 (0.55, 0.99) 0.045 0.27/0.33 0.76 (0.56, 1.04) 0.09
WHI 8/161 0.38/0.29 1.44 (0.48, 4.12) 0.49 0.38/0.26 1.76 (0.55, 5.56) 0.32
Combined
3 0.78 (0.58, 1.03) 0.078 0.80 (0.60, 1.08) 0.15
Latino MEC 104/673 0.38/0.41 0.83 (0.60, 1.16) 0.28 0.31/0.34 0.85 (0.60, 1.22) 0.39
WHI 20/207 0.30/0.48 0.42 (0.19, 0.84) 0.02 0.18/0.41 0.29 (0.11, 0.65) 0.006
Combined
3 0.74 (0.55, 1.00) 0.052 0.73 (0.53, 1.02) 0.065
Hawaiian MEC 27/344 0.33/0.34 0.80 (0.41, 1.59) 0.53 0.31/0.30 0.87 (0.43, 1.74) 0.69
All groups
2 MEC 426/3854 0.41/0.46 0.80 (0.69, 0.93) 0.0048 0.33/0.38 0.80 (0.68, 0.94) 0.0068
WHI 931/3755 0.45/0.50 0.83 (0.75, 0.92) 0.00059 0.36/0.41 0.79 (0.71, 0.88) 1.87610
25
Combined
3 0.82 (0.75, 0.89) 5.63610
26 0.79 (0.73, 0.87) 3.77610
27
1Odds ratio per allele obtained from logistic regression adjusting for age (continuous), 4 ancestry principal components, BMI (,25, 25-,30, $30 kg/m
2).
2P interaction with race/ethnicity in the MEC $0.63; P interaction with race/ethnicity in the WHI $0.21;
3Combined ORs were calculated using a fixed effects model.
doi:10.1371/journal.pone.0030390.t002
Table 3. Association between HNF1B variants and Type I and Type II endometrial cancer.
rs4430796 (A/G) rs7501939 (G/A)
Tumor type Study
Number of
cases/controls
Allele Frequency
Cases/Controls OR
1 (95% CI) P-value
Allele Frequency
Cases/Controls OR
1 (95% CI) P-value
Type I MEC 354/3854 0.41/0.46 0.82 (0.69, 0.94) 0.020 0.33/0.38 0.81 (0.68, 0.97) 0.019
WHI 837/3755 0.45/0.50 0.83 (0.74, 0.92) 0.00073 0.36/0.41 0.79 (0.71, 0.88) 4.45610
25
Combined
2 0.83 (0.76, 0.90) 2.79610
25 0.80 (0.73, 0.87) 1.00610
26
Type II MEC 45/3854 0.37/0.46 0.59 (0.37, 0.94) 0.025 0.32/0.38 0.66 (0.41, 1.07) 0.093
WHI 101/3755 0.47/0.50 0.86 (0.65, 1.15) 0.31 0.36/0.41 0.78 (0.58, 1.03) 0.093
Combined
2 0.78 (0.61, 0.99) 0.041 0.75 (0.58, 0.95) 0.020
1Odds ratio per allele obtained using polytomous logistic regression adjusting for age (continuous), 4 ancestry principal components, and BMI (,25, 25-,30,
$30 kg/m
2).
2Combined ORs were calculated using a fixed effects model.
doi:10.1371/journal.pone.0030390.t003
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SNP allele has also been associated with an increased risk of type 2
diabetes [3,4]. Diabetes is inversely associated with prostate cancer
[19], but positively associated with endometrial cancer [20].
Therefore we may expect that SNPs would often have an effect in
the same direction on both outcomes. The opposite effect of
rs4430796 on diabetes and endometrial cancer, however, does not
mirror the positive association between diabetes and endometrial
cancer risk. We observed significant associations between HNF1B
variants and endometrial cancer only among non-diabetics in both
studies. The lack of statistical significance among diabetics is likely
due to the small number of diabetics and thus limited power
(,40%) in detecting modest effects associated with these SNPs.
We also observed a potential interaction between HNF1B SNPs
and diabetes status in the WHI, but not in the MEC. It is possible
that this discrepancy was due to the fact that the magnitude of the
association between diabetes and endometrial cancer differed
between WHI (OR=1.34; 95% CI: 0.93, 1.91) and MEC
(OR=0.93; 95% CI: 0.64, 1.36). In our analysis, adjusting for
diabetes status had little effect on the SNP-endometrial cancer
relationships. Whether diabetes status influences the association
between HNF1B and endometrial cancer therefore remains
unclear; examination of potential interaction between diabetes
status and HNF1B in other endometrial cancer studies is
warranted.
The strengths of our study include a relatively large sample size
and the availability of comprehensive risk factor data for
confounder adjustment, as well as an ancestrally diverse
population. Limitations include non-centralized pathology review
in determining the endometrial cancer histology which can result
in misclassification of Type I and Type II tumors and can dilute
the difference in ORs, if any, between these two groups.
In summary, we provide additional evidence that HNF1B is
involved in endometrial cancer etiology. Future projects that
include fine-mapping/sequencing the HNF1B region and func-
tional studies are warranted to pinpoint the causal variants and the
biological mechanisms involved in endometrial carcinogenesis.
Supporting Information
Table S1 Gene-environment interactions between
HNF1B and endometrial cancer risk factors in the
Women’s Health Initiative Study (WHI).
(DOCX)
Table S2 Gene-environment interactions between
HNF1B and endometrial cancer risk factors in the
Multiethnic Cohort Study (MEC).
(DOCX)
Acknowledgments
The data and materials included in this report result from a collaboration
between the PAGE consortium, the Multiethnic Cohort study (MEC) and
the Women’s Health Initiative (WHI).
The authors thank the MEC cohort members for their participation and
Dr. Kristine Monroe for her invaluable contributions to the execution of
the Multiethnic Cohort study. The authors thank the WHI investigators
and staff for their dedication, and the study participants for making the
program possible. A full listing of WHI investigators can be found at:
http://www.whiscience.org/publications/WHI_investigators_shortlist.pdf.
Author Contributions
Conceived and designed the experiments: VWS FS CAH UP LLM CK.
Performed the experiments: VWS JH FS CK. Analyzed the data: VWS JH
FS CK. Wrote the paper: VWS JH FS MLC ED MDF BEH RDJ JSV
LRW SY CAH UP LLM CK.
References
1. Spurdle AB, Thompson DJ, Ahmed S, Ferguson K, Healey CS, et al. (2011)
Genome-wide association study identifies a common variant associated with risk
of endometrial cancer. Nat Genet 43: 451–454.
2. Elliott KS, Zeggini E, McCarthy MI, Gudmundsson J, Sulem P, et al. (2010)
Evaluation of association of HNF1B variants with diverse cancers: collaborative
analysis of data from 19 genome-wide association studies. PLoS One 5: e10858.
Table 4. Association between HNF1B variants and endometrial cancer by diabetes status.
rs4430796 (A/G) rs7501939 (G/A)
Diabetes
Status Study
Number of
cases/controls
Allele Frequency
Cases/Controls OR
1 (95% CI)
Allele Frequency
Cases/Controls OR
1 (95% CI)
Non-diabetic MEC 388/3556 0.41/0.46 0.80 (0.69, 0.94) 0.33/0.38 0.80 (0.68,
0.94)
WHI 887/3610 0.45/0.50 0.81 (0.73, 0.91) 0.35/0.41 0.77 (0.69,
0.86)
Combined
2 0.81 (0.74, 0.88) 0.78 (0.71,
0.85)
Diabetic MEC 38/298 0.42/0.47 0.76 (0.44, 1.30) 0.36/0.38 0.90 (0.52,
1.57)
WHI 44/143 0.57/0.49 1.41 (0.85, 2.37) 0.49/0.43 1.37 (0.80,
2.37)
Combined
2 1.05 (0.73, 1.53) 1.11 (0.76,
1.64)
1Odds ratio per allele obtained from logistic regression adjusting for age (continuous), 4 ancestry principal components and BMI.
2Combined ORs were calculated using a fixed effects model.
Test for interaction was assessed using log-likelihood test statistics comparing models with and without the interaction term.
P interaction for rs4430796 was 0.028 (WHI) and 0.93 (MEC); P interaction for rs7501939 was 0.054 (WHI) and 0.58 (MEC).
doi:10.1371/journal.pone.0030390.t004
HNF1B and Endometrial Cancer Risk
PLoS ONE | www.plosone.org 5 January 2012 | Volume 7 | Issue 1 | e303903. Gudmundsson J, Sulem P, Steinthorsdottir V, Bergthorsson JT, Thorleifsson G,
et al. (2007) Two variants on chromosome 17 confer prostate cancer risk, and
the one in TCF2 protects against type 2 diabetes. Nat Genet 39: 977–983.
4. Voight BF, Scott LJ, Steinthorsdottir V, Morris AP, Dina C, et al. (2010) Twelve
type 2 diabetes susceptibility loci identified through large-scale association
analysis. Nat Genet 42: 579–589.
5. Matise TC, Ambite JL, Buyske S, Carlson CS, Cole SA, et al. (2011) The Next
PAGE in understanding complex traits: design for the analysis of Population
Architecture Using Genetics and Epidemiology (PAGE) Study. Am J Epidemiol
174: 849–859.
6. Kolonel LN, Henderson BE, Hankin JH, Nomura AM, Wilkens LR, et al. (2000)
A multiethnic cohort in Hawaii and Los Angeles: baseline characteristics.
Am J Epidemiol 151: 346–357.
7. (1998) Design of the Women’s Health Initiative clinical trial and observational
study. The Women’s Health Initiative Study Group. Control Clin Trials 19:
61–109.
8. Curb JD, McTiernan A, Heckbert SR, Kooperberg C, Stanford J, et al. (2003)
Outcomes ascertainment and adjudication methods in the Women’s Health
Initiative. Ann Epidemiol 13: S122–128.
9. Felix AS, Weissfeld JL, Stone RA, Bowser R, Chivukula M, et al. (2010) Factors
associated with Type I and Type II endometrial cancer. Cancer Causes Control
21: 1851–1856.
10. Prat J (2004) Prognostic parameters of endometrial carcinoma. Hum Pathol 35:
649–662.
11. Ronnett BM, Zaino R, Ellenson LH, Kurman RJ (2002) Endometrial Cancer.
In: Kurman RJ, ed. Blaustein’s Pathology of the Female Genital Tract. Fifth ed.
New York: Springer. pp 501–559.
12. Sherman ME (2000) Theories of endometrial carcinogenesis: a multidisciplinary
approach. Mod Pathol 13: 295–308.
13. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, et al. (2006)
Principal components analysis corrects for stratification in genome-wide
association studies. Nat Genet 38: 904–909.
14. Bach I, Yaniv M (1993) More potent transcriptional activators or a
transdominant inhibitor of the HNF1 homeoprotein family are generated by
alternative RNA processing. EMBO J 12: 4229–4242.
15. Edghill EL, Bingham C, Ellard S, Hattersley AT (2006) Mutations in hepatocyte
nuclear factor-1beta and their related phenotypes. J Med Genet 43: 84–90.
16. Horikawa Y, Iwasaki N, Hara M, Furuta H, Hinokio Y, et al. (1997) Mutation in
hepatocyte nuclear factor-1 beta gene (TCF2) associated with MODY. Nat
Genet 17: 384–385.
17. Glinsky GV, Glinskii AB, Stephenson AJ, Hoffman RM, Gerald WL (2004)
Gene expression profiling predicts clinical outcome of prostate cancer. J Clin
Invest 113: 913–923.
18. Harries LW, Perry JR, McCullagh P, Crundwell M (2010) Alterations in
LMTK2, MSMB and HNF1B gene expression are associated with the
development of prostate cancer. BMC Cancer 10: 315.
19. Waters KM, Henderson BE, Stram DO, Wan P, Kolonel LN, et al. (2009)
Association of diabetes with prostate cancer risk in the multiethnic cohort.
Am J Epidemiol 169: 937–945.
20. Cook LS, Weiss NS, Doherty JA, Chen C (2006) Endometrial Cancer. In:
Schottenfeld D, Fraumeni JF, Jr., eds. Cancer Epidemiology and Prevention.
Third ed. New York: Oxford University Press. pp 1027–1043.
HNF1B and Endometrial Cancer Risk
PLoS ONE | www.plosone.org 6 January 2012 | Volume 7 | Issue 1 | e30390